Roanna Ruiz

Stock Analyst at Leerink Partners

(0)
# 4663
Out of 5,240 analysts
73
Total ratings
30.56%
Success rate
-18.90%
Average return
18 Stocks
Name Action Price Target Current % Upside Ratings Updated
Vir Biotechnology
Maintains: Outperform
18 20
10.63 88.15% 4 Jan 13, 2025
ARS Pharmaceuticals
Maintains: Outperform
26 27
11.58 133.16% 4 Jan 13, 2025
Aquestive Therapeuti...
Maintains: Outperform
12 13
3.15 312.7% 3 Oct 25, 2024
Ardelyx
Initiates Coverage On: Outperform
14
5.59 150.45% 1 Apr 5, 2024
United Therapeutics
Initiates Coverage On: Outperform
330
369.99 -10.81% 1 Feb 5, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
58
47.28 22.67% 1 Aug 15, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Market Perform
25
52.97 -52.8% 1 Apr 11, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Market Perform
9 2
n/a n/a 4 Apr 4, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Market Perform
49
4.91 897.96% 10 Feb 9, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
6 5
3.27 52.91% 4 Jan 27, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
12 13
3.49 272.49% 7 Jan 27, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Market Perform
8 6
3.22 86.34% 6 Jan 27, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
19
24.29 -21.78% 1 Dec 20, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
110 120
94.43 27.08% 3 Nov 15, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Market Perform
75 50
31.98 56.35% 7 Nov 3, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Market Perform
23 27
n/a n/a 7 Oct 25, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Market Perform
3 2
0.53 277.36% 6 Oct 19, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Market Perform
720 80
n/a n/a 3 Jul 14, 2022